Impact of P2Y12-mediated platelet reactivity on myocardial perfusion of patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a cardiac magnetic resonance study
| Autor: | Chiara Bucciarelli-Ducci, Alessandra Cadoni, Alessio La Manna, Antonella Salemi, Corrado Tamburino, Piera Capranzano, Irene Cascone, Claudia Tamburino, Davide Capodanno |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Medicine(all)
medicine.medical_specialty Prasugrel Radiological and Ultrasound Technology medicine.diagnostic_test business.industry medicine.medical_treatment Percutaneous coronary intervention Clopidogrel medicine.disease P2Y12 Internal medicine Angiography Poster Presentation cardiovascular system medicine Cardiology ST segment Radiology Nuclear Medicine and imaging cardiovascular diseases Myocardial infarction Cardiology and Cardiovascular Medicine business Ticagrelor medicine.drug |
| Zdroj: | Journal of Cardiovascular Magnetic Resonance |
| ISSN: | 1532-429X 1097-6647 |
| Popis: | Background Whether high platelet reactivity (HPR) at the time of angiography is associated with worse myocardial reperfusion after primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI) is unknown. This study aimed to assess the impact of HPR on infarct size and reperfusion injury determined by cardiac magnetic resonance (CMR) in patients with STEMI undergoing PPCI. Methods Patients with STEMI undergoing PPCI and pretreated with a P2Y12-receptor antagonist (clopidogrel, prasugrel or ticagrelor) underwent platelet function testing at the time of angiography and a CMR from 7 to 10 days after the index event. Platelet function testing was performed with the VerifyNow assay. HPR was defined according to expert consensus definitions. Central core laboratorymasked analyses for quantified ventricular function |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink